13058_2019_1221_MOESM2_ESM.xlsx (33.8 kB)
MOESM2 of Prediction and clinical utility of a contralateral breast cancer risk model
dataset
posted on 2019-12-18, 07:23 authored by Daniele Giardiello, Ewout Steyerberg, Michael Hauptmann, Muriel Adank, Delal Akdeniz, Carl Blomqvist, Stig Bojesen, Manjeet Bolla, Mariël Brinkhuis, Jenny Chang-Claude, Kamila Czene, Peter Devilee, Alison Dunning, Douglas Easton, Diana Eccles, Peter Fasching, Jonine Figueroa, Henrik Flyger, Montserrat García-Closas, Lothar Haeberle, Christopher Haiman, Per Hall, Ute Hamann, John Hopper, Agnes Jager, Anna Jakubowska, Audrey Jung, Renske Keeman, Iris Kramer, Diether Lambrechts, Loic Marchand, Annika Lindblom, Jan Lubiński, Mehdi Manoochehri, Luigi Mariani, Heli Nevanlinna, Hester Oldenburg, Saskia Pelders, Paul Pharoah, Mitul Shah, Sabine Siesling, Vincent Smit, Melissa Southey, William Tapper, Rob Tollenaar, Alexandra Broek, Carolien Deurzen, Flora Leeuwen, Chantal Ongeval, Laura Van’t Veer, Qin Wang, Camilla Wendt, Pieter Westenend, Maartje Hooning, Marjanka SchmidtAdditional file 2 Figure S1. Graphical assessment of non-linear relationship of age with contralateral breast cancer risk. Figure S2. Visual assessment of calibration through calibration plots in the internal-external cross-validation at 5 years for the contralateral breast cancer risk model with BRCA mutation information. Figure S3. Visual assessment of calibration through calibration plots in the internal-external cross-validation at 10 years for the contralateral breast cancer risk model with BRCA mutation information. Figure S4. Decision curve analysis at 5 years for the contralateral breast cancer risk model including BRCA1/2 mutation information. Figure S5. Results of the leave-one-study-out cross-validation for the contralateral breast cancer risk model at 5 and 10 years without BRCA mutation information. Figure S6. Visual assessment of calibration through calibration plots in the internal-external cross-validation at 5 years for the contralateral breast cancer risk model without BRCA mutation information. Figure S7. Visual assessment of calibration through calibration plots in the internal-external cross-validation at 10 years for the contralateral breast cancer risk model without BRCA mutation information. Figure S8. Density distribution of 10-year predicted absolute risk in patients with no family history and patients with a family history. Figure S9. Decision curve analysis at 5 years for the contralateral breast cancer risk model without BRCA mutation information. Figure S10. Decision curve analysis at 10 years for the contralateral breast cancer risk model without BRCA mutation information. Figure S11. Assessment of inclusion of information of contralateral preventive mastectomy (CPM).
